Wellving Asset Management have announced their seminar tour scheduled in for November through December. Analysts and advisers will be attending and the team will be headed by President Yakumo Naoko and Vice President Finnegan Meyers.
Existing clients of Wellving Asset Management will be extended free invitations to the event as a “thank you to their loyalty over the 9 years.”
Founder Yakumo Naoko and CEO/VP Mr Finnegan Meyers will be in attendance to meet, great and answer all questions provided.
The seminar will be focused on current economic affairs, current and future market insights along with an Q & A session at the end.
Locations confirmed so far:
Australia
New Zealand
UK
Germany
Canada
Venues to be announced soon along with any added locations.
Clients can visit Wellving’s website to contact for more information and tickets.
Wellving AM offers clients access to a wide range of financial products including fixed income securities, interest rate swaps, foreign exchange, equities, equity derivatives, credit derivatives, commercial real estate, commodities, futures, and structured products. They also provide a comprehensive range of services to the financial community, including trade execution, broker-dealer services, clearing, processing, information, and other back-office services.
Their team of advisors and financial experts have a wealth of experience spanning may industry sectors, they are happy to discuss your individual needs and evaluate your portfolio.
Let’s block ads! (Why?)
ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…
Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…
QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…
SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…
DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…
Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…